Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CSL ( (AU:CSL) ) just unveiled an announcement.
CSL Limited has announced the appointment of Gordon Naylor as a director, effective December 1, 2025. This appointment is accompanied by the disclosure of Naylor’s interests in CSL securities, including 39,719 ordinary shares directly held and 54,992 shares held indirectly through Netwealth Investments Limited. This move is significant for CSL as it strengthens its leadership team with Naylor’s expertise, potentially impacting its strategic direction and stakeholder confidence.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$283.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and manufacturing of innovative medicines and vaccines. The company is known for its contributions to global health through its range of products, including plasma-derived therapies and influenza vaccines.
Average Trading Volume: 1,197,433
Technical Sentiment Signal: Sell
Current Market Cap: A$89.09B
See more data about CSL stock on TipRanks’ Stock Analysis page.